Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses

Antiviral Research

Volumn 78, Issue 1, 2008, Pages 26-36

  Spurgers, Kevin B ^a   Sharkey, C Matthew ^a   Warfield, Kelly L ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antisense; Phosphorodiamidate morpholino oligomer; RNA interference; RNA virus; siRNA

Indexed keywords

ALN RSV01; ANTISENSE OLIGODEOXYNUCLEOTIDE; AVI 4065; AVI 4126; BEVASIRANIB; COMPLEMENTARY RNA; DOUBLE STRANDED RNA; FOMIVIRSEN; ISIS 113715; MESSENGER RNA; OBLIMERSEN; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; SHORT HAIRPIN RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ARENAVIRUS; ARTICLE; BINDING SITE; BIOLOGICAL WARFARE; CATALYSIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; DENGUE VIRUS; DRUG EFFICACY; EBOLA VIRUS; FILOVIRUS; FLAVIVIRUS; GENE TARGETING; HUMAN; IN VIVO STUDY; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; JAPANESE ENCEPHALITIS VIRUS; MAMMAL CELL; MARBURG VIRUS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RNA DEGRADATION; RNA INTERFERENCE; RNA TRANSLATION; RNA VIRUS; SARS CORONAVIRUS; UNSPECIFIED SIDE EFFECT; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; GUINEA PIGS; HUMANS; MICE; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA VIRUS INFECTIONS; RNA VIRUSES; RNA, SMALL INTERFERING; RNA, VIRAL;

ANIMALIA; MAMMALIA; RNA VIRUSES;

EID: 40849119735     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.12.008     Document Type: Article

References (92)

1. Akerstrom S., Mirazimi A., and Tan Y.J. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S. Antiviral Res. 73 3 (2007) 219-227
2. Amantana A., Moulton H.M., Cate M.L., Reddy M.T., Whitehead T., Hassinger J.N., Youngblood D.S., and Iversen P.L. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18 4 (2007) 1325-1331
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 2 (2004) 281-297
4. Bausch D., Sprecher A.G., Jeffs B., and Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs under outbreak conditions. Antiviral Res. 78 (2008) 150-161
5. Bazhutin N.B., Belanov E.F., Spiridonov V.A., Voitenko A.V., Krivenchuk N.A., Krotov S.A., Omel'chenko N.I., Tereshchenko A., and Khomichev V.V. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Vopr. Virusol. 37 3 (1992) 153-156
6. Beigel J., and Bray M. Current and future therapy of severe influenza A virus infections. Antiviral Res. 78 (2008) 91-102
7. Bennasser Y., Le S.Y., Benkirane M., and Jeang K.T. Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 22 5 (2005) 607-619
8. Bennink J.R., and Palmore T.N. The promise of siRNAs for the treatment of influenza. Trends Mol. Med. 10 12 (2004) 571-574
9. Bitko V., and Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 1 (2001) 34
10. Burrer R., Neuman B.W., Ting J.P., Stein D.A., Moulton H.M., Iversen P.L., Kuhn P., and Buchmeier M.J. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models. J. Virol. 81 11 (2007) 5637-5648
11. Busen. Purification, subunit structure, and serologicai analysis of calf thymus ribonuclease H I. J. Biol. Chem. 255 19 (1980) 9434-9443
12. Busen W., Peters J.H., and Hausen P. Ribonuclease H levels during the response of bovine lymphocytes to concanavalin A. Eur. J. Biochem. 74 1 (1977) 203-208
13. Chan J.H., Lim S., and Wong W.S. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 33 5/6 (2006) 533-540
14. Cheung T.K., and Poon L.L. Biology of influenza a virus. Ann. N.Y. Acad. Sci. 1102 (2007) 1-25
15. de Fougerolles A., Vornlocher H.P., Maraganore J., and Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6 6 (2007) 443-453
16. Deas T.S., Bennett C.J., Jones S.A., Tilgner M., Ren P., Behr M.J., Stein D.A., Iversen P.L., Kramer L.D., Bernard K.A., and Shi P.Y. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51 7 (2007) 2470
17. Deas T.S., Binduga-Gajewska I., Tilgner M., Ren P., Stein D.A., Moulton H.M., Iversen P.L., Kauffman E.B., Kramer L.D., and Shi P.Y. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79 8 (2005) 4599-4609
18. Debart F., Abes S., Deglane G., Moulton H.M., Clair P., Gait M.J., Vasseur J.J., and Lebleu B. Chemical modifications to improve the cellular uptake of oligonucleotides. Curr. Top. Med. Chem. 7 7 (2007) 727-737
19. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., and Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 20 (2003) 1967-1976
20. Eder P.S., Walder R.Y., and Walder J.A. Substrate specificity of human RNase H1 and its role in excision repair of ribose residues misincorporated in DNA. Biochimie 75 1/2 (1993) 123-126
21. Elbashir S.M., Harborth J., Weber K., and Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26 2 (2002) 199-213
22. Enterlein S., Warfield K.L., Swenson D.L., Stein D.A., Smith J.L., Gamble C.S., Kroeker A.D., Iversen P.L., Bavari S., and Muhlberger E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50 3 (2006) 984-993
23. Feldmann H. Marburg hemorrhagic fever-the forgotten cousin strikes. N. Engl. J. Med. 355 9 (2006) 866-869
24. Fowler T., Bamberg S., Moller P., Klenk H.D., Meyer T.F., Becker S., and Rudel T. Inhibition of Marburg virus protein expression and viral release by RNA interference. J. Gen. Virol. 86 Pt 4 (2005) 1181-1188
25. Fritz J.H., Girardin S.E., and Philpott D.J. Innate immune defense through RNA interference. Sci. STKE 2006 339 (2006) pe27
26. Ge Q., Filip L., Bai A., Nguyen T., Eisen H.N., and Chen J. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. U.S.A. 101 23 (2004) 8676-8681
27. Ge Q., Pastey M., Kobasa D., Puthavathana P., Lupfer C., Bestwick R.K., Iversen P.L., Chen J., and Stein D.A. Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 50 11 (2006) 3724-3733
28. Geary R.S., Henry S.P., and Grillone L.R. Fomivirsen: clinical pharmacology and potential drug interactions. Clin. Pharmacokinet. 41 4 (2002) 255-260
29. Geisbert T.W., Hensley L.E., Kagan E., Yu E.Z., Geisbert J.B., Daddario-DiCaprio K., Fritz E.A., Jahrling P.B., McClintock K., Phelps J.R., Lee A.C., Judge A., Jeffs L.B., and MacLachlan I. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193 12 (2006) 1650-1657
30. Gould E., Solomon T., and Mackenzie J. Does antiviral therapy have a role in the control of Japanese encephalitis?. Antiviral Res. 78 (2008) 140-149
31. Grimm D., Streetz K.L., Jopling C.L., Storm T.A., Pandey K., Davis C.R., Marion P., Salazar F., and Kay M.A. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441 7092 (2006) 537-541
32. Gunther S., and Lenz O. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41 4 (2004) 339-390
33. Haasnoot J., de Vries W., Geutjes E.J., Prins M., de Haan P., and Berkhout B. The ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3 6 (2007) e86
34. Halstead S.B. Dengue. Lancet 370 (2007) 1644-1652
35. Hatta T., Nakagawa Y., Takai K., Nakada S., Yokota T., and Takaku H. Inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by unmodified, phosphorothioated, and liposomally encapsulated oligonucleotides. Biochem. Biophys. Res. Commun. 223 2 (1996) 341-346
36. Hatta T., Takai K., Nakada S., Yokota T., and Takaku H. Specific inhibition of influenza virus RNA polymerase and nucleoprotein genes expression by liposomally endocapsulated antisense phosphorothioate oligonucleotides: penetration and localization of oligonucleotides in clone 76 cells. Biochem. Biophys. Res. Commun. 232 2 (1997) 545-549
37. Henschel A., Buchholz F., and Habermann B. DEQOR: a web-based tool for the design and quality control of siRNAs. Nucleic Acids Res. 32 (2004) W113-W120 (Web Server issue)
38. Holden K.L., Stein D.A., Pierson T.C., Ahmed A.A., Clyde K., Iversen P.L., and Harris E. Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3′ stem-loop structure. Virology 344 2 (2006) 439-452
39. Jason T.L., Koropatnick J., and Berg R.W. Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201 1 (2004) 66-83
40. John M., Constien R., Akinc A., Goldberg M., Moon Y.A., Spranger M., Hadwiger P., Soutschek J., Vornlocher H.P., Manoharan M., Stoffel M., Langer R., Anderson D.G., Horton J.D., Koteliansky V., and Bumcrot D. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449 7163 (2007) 745-747
41. Johnson N.P., and Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull. Hist. Med. 76 1 (2002) 105-115
42. Kachko A.V., Ivanova A.V., Protopopova E.V., Netesov V., and Loktev V.B. Inhibition of West Nile virus replication by short interfering RNAs. Dokl. Biochem. Biophys. 410 (2006) 260-262
43. Khan S.H., Goba A., Chu M., Roth C., Healing T., Marx A., Fair J., Guttieri M., Ferro P., Imes T., Monagin C., Garry R., and Bausch D. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 78 (2008) 103-115
44. Khromykh A.A., Kondratieva N., Sgro J.Y., Palmenberg A., and Westaway E.G. Significance in replication of the terminal nucleotides of the flavivirus genome. J. Virol. 77 19 (2003) 10623-10629
45. Kinney R.M., Huang C.Y., Rose B.C., Kroeker A.D., Dreher T.W., Iversen P.L., and Stein D.A. Inhibition of dengue virus serotypes 1-4 in vero cell cultures with morpholino oligomers. J. Virol. 79 8 (2005) 5116-5128
46. Krieg A.M., and Stein C.A. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?. Antisense Res. Dev. 5 4 (1995) 241
47. Kumar P., Lee S.K., Shankar P., and Manjunath N. A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med. 3 4 (2006) e96
48. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., and Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 7149 (2007) 39-43
49. le Sage C., and Agami R. Immense promises for tiny molecules: uncovering miRNA functions. Cell Cycle 5 13 (2006) 1415-1421
50. Lee N.S., and Rossi J.J. Control of HIV-1 replication by RNA interference. Virus Res. 102 1 (2004) 53-58
51. Lee R.C., Feinbaum R.L., and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 5 (1993) 843-854
52. Lee S.H., and Sinko P.J. siRNA-getting the message out. Eur. J. Pharm. Sci. 27 5 (2006) 401-410
53. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., and Kim V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature 425 6956 (2003) 415-419
54. Leffel E.K., and Reed D.S. Marburg and Ebola viruses as aerosol threats. Biosecur. Bioterror. 2 3 (2004) 186-191
55. Li B.J., Tang Q., Cheng D., Qin C., Xie F.Y., Wei Q., Xu J., Liu Y., Zheng B.J., Woodle M.C., Zhong N., and Lu P.Y. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat. Med. 11 9 (2005) 944-951
56. Li Y.C., Kong L.H., Cheng B.Z., and Li K.S. Construction of influenza virus siRNA expression vectors and their inhibitory effects on multiplication of influenza virus. Avian Dis. 49 4 (2005) 562-573
57. Lim T.W., Yuan J., Liu Z., Qiu D., Sall A., and Yang D. Nucleic-acid-based antiviral agents against positive single-stranded RNA viruses. Curr. Opin. Mol. Ther. 8 2 (2006) 104-107
58. Mercorelli, B., Sinigalia, E., Loregian, A., Palu, G., 2007. Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev. Med. Virol. Nov 16 (epub ahead of print).
59. Mizuta T., Fujiwara M., Hatta T., Abe T., Miyano-Kurosaki N., Shigeta S., Yokota T., and Takaku H. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat. Biotechnol. 17 6 (1999) 583-587
60. Muller S., and Gunther S. Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of lassa virus. Antimicrob. Agents Chemother. 51 6 (2007) 2215-2218
61. Neuman B.W., Stein D.A., Kroeker A.D., Churchill M.J., Kim A.M., Kuhn P., Dawson P., Moulton H.M., Bestwick R.K., Iversen P.L., and Buchmeier M.J. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79 15 (2005) 9665-9676
62. O'Brien L. Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antiviral Res. 75 1 (2007) 20-29
63. Ong S.P., Choo B.G., Chu J.J., and Ng M.L. Expression of vector-based small interfering RNA against West Nile virus effectively inhibits virus replication. Antiviral Res. 72 3 (2006) 216-223
64. Orr R.M. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision. Curr. Opin. Mol. Ther. 3 3 (2001) 288-294
65. Pei Y., and Tuschl T. On the art of identifying effective and specific siRNAs. Nat. Methods 3 9 (2006) 670-676
66. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., and Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
67. Pooga M., Hallbrink M., Zorko M., and Langel U. Cell penetration by transportan. FASEB J. 12 1 (1998) 67-77
68. Prakash T.P., and Bhat B. 2′-Modified oligonucleotides for antisense therapeutics. Curr. Top. Med. Chem. 7 7 (2007) 641-649
69. Qin Z.L., Zhao P., Cao M.M., and Qi Z.T. siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA. J. Virol. Methods 145 2 (2007) 146-154
70. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., Horvitz H.R., and Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403 6772 (2000) 901-906
71. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., and Bellini W.J. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
72. Samuel M.A., and Diamond M.S. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80 19 (2006) 9349-9360
73. Satija N., and Lal S.K. The molecular biology of SARS coronavirus. Ann. N.Y. Acad. Sci. 1102 (2007) 26-38
74. Shah J.K., Garner H.R., White M.A., Shames D.S., and Minna J.D. sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database. BMC Bioinformat. 8 (2007) 178
75. Sioud M. RNA interference and innate immunity. Adv. Drug Deliv. Rev. 59 2/3 (2007) 153-163
76. Sontheimer E.J. Assembly and function of RNA silencing complexes. Nat. Rev. Mol. Cell Biol. 6 2 (2005) 127-138
77. Stein C.A., and Krieg A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4 2 (1994) 67-69
78. Stephenson M.L., and Zamecnik P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A. 75 1 (1978) 285-288
79. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489 1 (1999) 141-158
80. Summerton J.E. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr. Top. Med. Chem. 7 7 (2007) 651-660
81. Thacker P.D. An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power. JAMA 290 3 (2003) 317-319
82. Tilley L.D., Mellbye B.L., Puckett S.E., Iversen P.L., and Geller B.L. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: dose-response in mice infected with Escherichia coli. J. Antimicrob. Chemother. 59 1 (2007) 66-73
83. Tompkins S.M., Lo C.Y., Tumpey T.M., and Epstein S.L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U.S.A. 101 23 (2004) 8682-8686
84. Turchi J.J., Huang L., Murante R.S., Kim Y., and Bambara R.A. Enzymatic completion of mammalian lagging-strand DNA replication. Proc. Natl. Acad. Sci. U.S.A. 91 21 (1994) 9803-9807
85. Voinnet O. Induction and suppression of RNA silencing: insights from viral infections. Nat. Rev. Genet. 6 3 (2005) 206-220
86. Warfield K.L., Swenson D.L., Olinger G.G., Nichols D.K., Pratt W.D., Blouch R., Stein D.A., Aman M.J., Iversen P.L., and Bavari S. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2 1 (2006) e1
87. Weaver S.C., Ferro C., Barrera R., Boshell J., and Navarro J.C. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49 (2004) 141-174
88. Wu C.J., and Chan Y.L. Antiviral applications of RNAi for coronavirus. Expert Opin. Investig. Drugs 15 2 (2006) 89-97
89. Wu Y., Zhang G., Li Y., Jin Y., Dale R., Sun L.Q., and Wang M. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem. Biophys. Res. Commun. 365 2 (2008) 369-374
90. Ying S.Y., Chang D.C., Miller J.D., and Lin S.L. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol. Biol. 342 (2006) 1-18
91. Zheng B.J., Guan Y., Tang Q., Du C., Xie F.Y., He M.L., Chan K.W., Wong K.L., Lader E., Woodle M.C., Lu P.Y., Li B., and Zhong N. Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antivir. Ther. 9 3 (2004) 365-374
92. Zhou H., Jin M., Yu Z., Xu X., Peng Y., Wu H., Liu J., Liu H., Cao S., and Chen H. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res. 76 2 (2007) 186-193